Hostname: page-component-788cddb947-m6qld Total loading time: 0 Render date: 2024-10-14T20:43:05.109Z Has data issue: false hasContentIssue false
  • English
  • Français

Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: a post-mortem autoradiographic study

Published online by Cambridge University Press:  09 July 2009

R. Kerwin ,
P. Robinson  and
J. Stephenson
R. Kerwin*
Affiliation:
Departments of Neuroscience and Psychiatry, Institute of Psychiatry, London
P. Robinson
Affiliation:
Departments of Neuroscience and Psychiatry, Institute of Psychiatry, London
J. Stephenson
Affiliation:
Departments of Neuroscience and Psychiatry, Institute of Psychiatry, London
*
1 Address for correspondence: Dr R. Kerwin, Department of Neuroscience, Institute of Psychiatry, De Crespigny Park, London SE5 8AF.
Get access Rights & Permissions [Opens in a new window]

Synopsis

The distribution of cholecystokinin binding sites has been visualized and quantified by quantitative autoradiography in the human hippocampus from post-mortem brains of 11 controls and 11 schizophrenics. CCK receptors were localized to subiculum and parahippocampal gyrus. In the cortical areas there was a particularly dense lamination of receptors.

In the schizophrenic material a similar overall pattern was seen, but there were significant losses of receptors in CA1 subiculum and cortex. These findings confirm the distribution of CCK receptors in the retrohippocampal areas in man and also provide further support for earlier homogenate studies which have also shown a loss of CCK binding sites in schizophrenia. This effect was localized primarily to parahippocampal gyrus suggesting that CCK plays some role in the genesis of developmental abnormalities in this region.

Type
Original Articles
Information
Psychological Medicine , Volume 22 , Issue 1 , February 1992 , pp. 37 - 43
Copyright
Copyright © Cambridge University Press 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Referemces

Bogerts, B., Meertz, E. & Schonfeldt-Bausch, R. (1985). Basal ganglia and limbic system pathology in schizophrenia. Archives of General Psychiatry 42, 784–791.Google Scholar
Brown, R., Colter, N., Corsellis, J. A. W., Crow, T. J., Frith, C. D., Jagoe, R., Johnstone, E. C. & Marsh, L. (1986). Post-mortem evidence of structural brain changes in schizophrenia. Archives of General Psychiatry 43, 36–42.Google Scholar
Carruthers, B., Dawbarn, D., de Quidt, M., Ellison, P., Hunter, J. & Reynolds, G. P. (1984). Changes in neuropeptide content of amygdala in schizophrenia. British Journal of Pharmacology 81, 139P.Google Scholar
Chun, J. J. M., Makamura, M. J. & Shatz, C. J. (1987). Transient cells of the developing mammalian telencephalon are peptide immunoreactive neurones. Nature 325, 617–620.Google Scholar
Crow, T. J., Ferrier, I. N., Johnstone, E. C., Owens, D. G. C., Roberts, G. W., Lee, Y. C., Bloom, S. R. & Polak, J. M. (1982). Neuroendocrine aspects of schizophrenia. In Neuropeptides: Basic and Clinical Aspects (ed. Fink, G. and Whalley, L. J.), pp. 222–239. Churchill-Livingstone: Edinburgh.Google Scholar
Dietl, M. M., Probst, A. & Palacios, J. M. (1987). On the distribution of cholecystokinin receptor binding sites in the human brain: an autoradiographic study. Synapse 1, 169–183.Google Scholar
Falkai, P. & Bogerts, B. (1986). Cell loss in the hippocampus of schizophrenics. European Archives of Psychiatric and Neurological Science 23, 154–161.Google Scholar
Falkai, P. & Bogerts, B. (1989). Morphometric evidence for developmental disturbances in the brains of some schizophrenics. Schizophrenia Research 2, 99.Google Scholar
Farmery, S. M., Owen, F., Poulter, M. & Crow, T. J. (1985). Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sciences 36, 473–477.Google Scholar
Ferrier, I. N., Crow, T. J., Farmery, S. M., Owens, D. G. C., Roberts, G. W., Adrian, T. E. & Bloom, S. R. (1985). Reduced CCK in the limbic lobe in schizophrenia: a marker for the defect state in schizophrenia. Annals of the New York Academy of Sciences 448, 495–500.Google Scholar
Garcha, G. S., McHugh, P. R., Moran, T. H., Robinson, P. H. & Stephenson, J. D. (1987). Development of cholecystokinin receptors and suppression of ingestion and gastric emptying in the rat. Journal of Physiology 387, 93P.Google Scholar
Handelmann, G. E., Meyer, D. G., Beinfield, M. C. & Oertel, W. H. (1981). CCK containing terminals in the hippocampus are derived from intrinsic neurons. An immunohistological and radio immunological study. Brain Research 224, 181–185.Google Scholar
Herkenham, M. & McLean, S. (1986). Mismatches between receptor and transmitter localisations in the brain. In Quantitative Autoradiography (ed. Boast, C. A., Snowhill, E. W. and Altar, C.), pp. 137–171. Alan R. Liss: New York.Google Scholar
Innis, R. B. & Snyder, S. H. (1980). Distinct cholecystokinin receptors in brain and pancreas. Proclamations of the National Academy of Sciences 77, 6917–6921.Google Scholar
Jakob, H. & Beckmann, H. (1986). Prenatal development disturbances in the limbic allocortex in schizophrenics. Journal of Neural Transmission 65, 303–326.Google Scholar
Kohler, C. & Chan-Palay, V. C. (1982). The distribution of cholecystokinin-like immunoreactive neurons and nerve terminals in the retrohippocampal region in the rat and guinea-pig. Journal of Comparative Neurology 210, 136–146.Google Scholar
Kohler, C. & Chan-Palay, V. C. (1988). Cholecystokinin octapeptide (CCK-8) receptors in the hippocampal region: a comparative in vitro autoradiographic study in the rat, monkey and the post-mortem human brain. Neuroscience letters 90, 51–56.Google Scholar
Kovelman, J. A. & Scheibel, A. B. (1984). A neurohistological correlate of schizophrenia. Biological Psychiatry 191, 1601–1621.Google Scholar
Marley, P. D., Rehfeld, J. F. & Emson, P. C. (1984). Distribution and chromatographic characterisation of gastric and cholecystokinin in the rat central nervous system. Journal of Neurochemistry 42, 1523–1535.Google Scholar
Montgomery, S. & Green, M. C. D. (1988). The use of cholecystokinin in schizophrenia: a review. Psychological Medicine 18, 593–603.Google Scholar
Perry, R. H., Dockray, G. J., Dimaline, R., Perry, E. K., Blessed, G. & Tomlinson, D. E. (1981). Neuropeptides in Alzheimer's Disease, depression and schizophrenia. Journal of Neurological Science 51, 465–472.Google Scholar
Roberts, G. W., Ferrier, I. N., Lee, Y., Crow, T. J., Johnstone, E. C., Owens, D. G. C., Barceresa-Hamilton, A. J., MacGregor, G., O'Shaughnessy, D., Polack, J. M. & Bloom, S. R. (1983). Peptides: the limbic lobe and schizophrenia. Brain Research 288, 199–211.Google Scholar
Roberts, G. W. & Bruton, C. J. (1990). Notes from the graveyard: neuropathology and schizophrenia. Neuropathology and Applied Neurobiology 16, 3–16.Google Scholar
Somogyi, P., Hodgson, A. J., Smith, A. D., Nunzi, G., Gorio, A. & Wu, J. Y. (1984). Different populations of GABAergic neurons in the visual cortex and hippocampus contain somatostatin or cholecystokinin immunoreactive material. Journal of Neuroscience 4, 2590–2603.Google Scholar
Van-Dijk, A., Richards, J. G., Trzeciak, A., Gillessen, D. & Mohler, H. (1984). Cholecystokinin receptors: biochemical demonstration and autoradiographical localisation in rat brain and pancreas using 3H cholecystokinin as radioligand. Journal of Neuroscience 4, 1021–1033.Google Scholar